These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 8481595

  • 1. Rationale for the use of clodronate in osteoporosis.
    Kanis JA, McCloskey EV, Sirtori P, Khan S, Fern D, Eyres K, Aaron J, Beneton MN.
    Osteoporos Int; 1993; 3 Suppl 2():S23-8. PubMed ID: 8481595
    [Abstract] [Full Text] [Related]

  • 2. Clodronate and osteoporosis.
    Kanis JA, McCloskey EV, Beneton MN.
    Maturitas; 1996 May; 23 Suppl():S81-6. PubMed ID: 8865146
    [Abstract] [Full Text] [Related]

  • 3. Rationale for the use of alendronate in osteoporosis.
    Kanis JA, Gertz BJ, Singer F, Ortolani S.
    Osteoporos Int; 1995 Jan; 5(1):1-13. PubMed ID: 7703618
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA.
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [Abstract] [Full Text] [Related]

  • 5. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL, Goa KL.
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical trials with bisphosphonates.
    Lombardi A, Santora AC.
    Ann Ital Med Int; 1992 Jun; 7(3 Suppl):158S-165S. PubMed ID: 1297394
    [Abstract] [Full Text] [Related]

  • 8. Bisphosphonates in the treatment of disorders of mineral metabolism.
    Singer FR, Minoofar PN.
    Adv Endocrinol Metab; 1995 Jun; 6():259-88. PubMed ID: 7671099
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.
    McClung MR.
    Bone; 1996 Nov; 19(5 Suppl):195S-198S. PubMed ID: 8922662
    [Abstract] [Full Text] [Related]

  • 11. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
    Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F.
    Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates in prostate carcinoma.
    Adami S.
    Cancer; 1997 Oct 15; 80(8 Suppl):1674-9. PubMed ID: 9362435
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bisphosphonate therapy.
    Licata AA.
    Am J Med Sci; 1997 Jan 15; 313(1):17-22. PubMed ID: 9001162
    [Abstract] [Full Text] [Related]

  • 17. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Fitton A, McTavish D.
    Drugs; 1991 Feb 15; 41(2):289-318. PubMed ID: 1709854
    [Abstract] [Full Text] [Related]

  • 18. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH, Kanis JA, Powles TJ, McCloskey E, Hanson J, Ashley S.
    Can J Oncol; 1995 Dec 15; 5 Suppl 1():54-7. PubMed ID: 8853526
    [Abstract] [Full Text] [Related]

  • 19. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE.
    Br J Cancer; 1995 Nov 15; 72(5):1289-93. PubMed ID: 7577484
    [Abstract] [Full Text] [Related]

  • 20. The role of bisphosphonates in the prevention and treatment of osteoporosis.
    Papapoulos SE.
    Am J Med; 1993 Nov 30; 95(5A):48S-52S. PubMed ID: 8256796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.